ResMed Inc. RMD
222.00
0.11
0.05%
as of 25 Sep
- Market cap
- $31.9B
- P/E
- 21.3×
Follow RMD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
ResMed Inc. (RMD) Total debt
ResMed Inc.'s total debt at the end of fiscal 2026 was $399.4M, down 39.3% from $658.4M in fiscal 2025. Over the past ten years it has ranged from $270.0M (fiscal 2018) to $1.4B (fiscal 2023); the current reading is higher than 25% of that period. ResMed Inc. ranks 18th of 55 Medical Instruments & Supplies companies by total debt.
Total debt, annual
Annual
| Period | Total debt | Change |
|---|---|---|
| FY2026 | $399.4M | (39.33%) |
| FY2025 | $658.4M | (5.58%) |
| FY2024 | $697.3M | (51.28%) |
| FY2023 | $1.4B | 87.01% |
| FY2022 | $765.3M | 18.96% |
| FY2021 | $643.4M | (44.74%) |
| FY2020 | $1.2B | (7.52%) |
| FY2019 | $1.3B | 366.27% |
| FY2018 | $270.0M | (74.97%) |
| FY2017 | $1.1B | 23.51% |
Quarterly
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $399.4M | (1.18%) |
| Mar 2026 | $404.2M | 0.06% |
| Dec 2025 | $403.9M | (1.16%) |
| Sep 2025 | $408.7M | (37.93%) |
| 41 more quarters | Free account |
Against its own ten years
Low $270.0M
High $1.4B
Ten-year median
$731.3M
Current reading's percentile
25
Total debt against peers
| Company | Total debt |
|---|---|
| BDX Becton, Dickinson and Company compare | $13.5B |
| MDLN Medline Inc. compare | $12.6B |
| BAX Baxter International Inc. compare | $9.5B |
| SOLV Solventum Corporation compare | $5.3B |
| ALC Alcon compare | $4.7B |
| COO The Cooper Companies, Inc. compare | $2.5B |
| RGEN Repligen Corporation compare | $551.0M |
| RMD ResMed Inc. | $399.4M |
| WST West Pharmaceutical Services, Inc. compare | $202.9M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on RMD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement